What did @eve.everestt actually say?
After eight weeks of an unresolved elbow injury, the creator decided to add peptides on top of physical therapy. She's running CJC-1295 paired with ipamorelin, which she says will help with "muscle recovery and sleep and fat loss," and TB-500 to "accelerate the healing process." She also picked up Melanotan II, or as she called it, "Milano T10," because she wants a tan. She's planning an eight-week run and hopes these compounds speed up what PT is already doing.
That's a three-peptide stack with three very different mechanisms and very different risk profiles. She presented it casually, the way someone might talk about adding a new supplement, and that framing is where the first problems start.
Does the science back this up?
The evidence is a patchwork of animal data, small human studies, and a lot of inference. TB-500's active fragment, Thymosin Beta-4, has shown genuine tissue-repair signals in preclinical work, but controlled human trials on tendon or elbow injuries specifically are essentially nonexistent. CJC-1295 with ipamorelin does stimulate growth hormone release, and there's legitimate clinical interest in GH secretagogues for body composition and recovery, but the jump from GH pulse to "healed elbow" is a long one.
- TB-500: Goldstein et al. (2012, Annals of the New York Academy of Sciences) documented Thymosin Beta-4's role in wound healing and actin regulation in animal models. Human connective tissue data is sparse.
- CJC-1295: Ionescu and Frohman (2006, Journal of Clinical Endocrinology and Metabolism) showed sustained GH elevation in healthy adults, but recovery from orthopedic injury was not studied.
- Ipamorelin: Raun et al. (1998, European Journal of Endocrinology) established its selectivity as a GH secretagogue with minimal cortisol or prolactin side effects, which is a point in its favor compared to older peptides.
None of these studies were looking at amateur athletes with eight-week-old elbow injuries. Extrapolation here is doing a lot of heavy lifting.
What did they get wrong (or right)?
She gets partial credit for keeping PT in the picture. Framing peptides as something layered on top of physical therapy, not as a replacement, is the right instinct. The research that does exist on GH secretagogues and soft tissue repair suggests any benefit would be adjunctive, not standalone.
Where she goes wrong is Melanotan II. Tossing in a melanocortin agonist with a "why not" attitude ignores a real risk profile. Melanotan II is not approved by the FDA for any indication. Studies, including Langan et al. (2021, Dermatologic Surgery), have documented associations with mole changes, nausea, spontaneous erections, and potential melanoma risk with unregulated use. It does not belong in the same sentence as a soft tissue recovery protocol, and adding it casually to an injury stack is a genuine problem worth naming plainly.
She also slightly overstates what CJC-1295 and ipamorelin are doing. They stimulate GH release. GH has downstream effects on IGF-1 and tissue repair, but calling this a direct muscle recovery tool without that nuance flattens the mechanism in a way that could mislead viewers.
What should you actually know?
These peptides are not FDA-approved drugs. They exist in a compounding gray zone in the US and are outright prohibited in most competitive sports (WADA banned list includes TB-500 and GH secretagogues). Anyone sourcing these outside a licensed telehealth provider is getting research-grade or gray-market material with no quality guarantee.
Eight weeks is also not a short injury timeline for an elbow, particularly if it involves a tendon. Lateral epicondylitis, for example, can take six months to a year to resolve with consistent PT. The frustration driving this video is understandable. The solution, though, should start with a sports medicine physician or orthopedist confirming what the injury actually is before layering in compounds that alter systemic hormone signaling.
- TB-500 is not a proven elbow injury treatment in humans. The mechanism is plausible, but plausible is not the same as proven.
- Melanotan II adds cosmetic risk for zero recovery benefit. This one should be removed from the stack entirely.
- GH secretagogues have a better safety signal than many compounds in this category, but they still require clinical supervision to use responsibly.